-+ 0.00%
-+ 0.00%
-+ 0.00%

Vext adjusted EBITDA climbs 22% to US$3.44 million in Q2 FY26; net loss narrows to US$315,000

PUBT·08/20/2026 20:31:38
Listen to the news
Vext adjusted EBITDA climbs 22% to US$3.44 million in Q2 FY26; net loss narrows to US$315,000
  • Vext Science posted Q2 2026 sales of USD 12.12 million, flat versus Q1 2026 as Ohio growth offset the Arizona cultivation wind-down.
  • Net loss narrowed 79% year over year to USD 315,000; adjusted EBITDA (non-IFRS) rose 22% from Q1 to USD 3.44 million.
  • Operating cash flow was USD 1.18 million; management cited a deliberate Ohio inventory build to support second-half growth.
  • Fairfield opened as the sixth Ohio dispensary; the Arizona cultivation wind-down was completed, with the Eloy property held for sale.
  • Eric Offenberger said capital is being redeployed from Arizona cultivation to Ohio retail, where incremental invested capital earns the highest return.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vext Science Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608201630NEWSFILECNPR____20260820_310639_1) on August 20, 2026, and is solely responsible for the information contained therein.